This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Erin Shammel Baker is an American bioanalytical chemist specializing in developing ion mobility-mass spectrometry hybrid instruments for biological and environmental applications. Baker is an expert in the research of perfluoroalkyl and polyfluoroalkyl substances analysis.
Truck terminals in proximity to industrial clusters, machinery and manufacturing units, agro-processing zones, and integrated cold-chain storage facilities will be planned to build the export-ready and quick logistics infrastructure. The HHBTMSM Expressway will have a separate provision for the optical fiber connectivity and gas pipelines, turning the greenfield expressway into a 'digital-ready' utility corridor.
==== Season 1 ==== At the beginning of the series, the Roys gather to celebrate Logan's 80th birthday, where it is assumed he will step down as CEO and name Kendall as his successor. However, he shocks his family when he announces he will stay on as CEO and hands them documents naming Marcia as his chief trustee upon his death. Logan suffers a debilitating stroke later that day and is admitted to the hospital, where the rest of his family and inner circle debate how to steward the company while he is incapacitated. Logan soon recovers and announces at a gala event that he will remain CEO, but continues displaying erratic behavior. Kendall plots a vote of no confidence against his father along with Roman and several members of the company's senior management, but it ultimately fails, in part because Logan refuses to leave the room during the vote and instead berates several board members into siding with him, while firing everyone who voted for the motion (including Kendall). Over the following months, Logan remains at odds with his children: Shiv goes to work as a political consultant for presidential candidate Gil Eavis, a Democratic Senator who despises Logan and Waystar, while Kendall - a recovering addict - relapses and derails a family therapy session intended to allay public concerns over the company's stability. At Shiv's wedding, Logan learns that Kendall has plotted a hostile takeover of the company alongside his friend Stewy and Logan's nemesis Sandy Furness.
== Indications and uses == Glycated hemoglobin testing is recommended for both checking the blood sugar control in people who might be prediabetic and monitoring blood sugar control in patients with more elevated levels, termed diabetes mellitus. For a single blood sample, it provides far more revealing information on glycemic behavior than a fasting blood sugar value. However, fasting blood sugar tests are crucial in making treatment decisions. The American Diabetes Association guidelines are similar to others in advising that the glycated hemoglobin test be performed at least twice a year in patients with diabetes who are meeting treatment goals (and who have stable glycemic control) and quarterly in patients with diabetes whose therapy has changed or who are not meeting glycemic goals. Glycated hemoglobin measurement is not appropriate where a change in diet or treatment has been made within six weeks. Likewise, the test assumes a normal red blood cell aging process and mix of hemoglobin subtypes (predominantly HbA in normal adults). Hence, people with recent blood loss, hemolytic anemia, or genetic differences in the hemoglobin molecule (hemoglobinopathy) such as sickle-cell disease and other conditions, as well as those who have donated blood recently, are not suitable for this test. Due to glycated hemoglobin's variability, additional measures should be checked in patients at or near recommended goals.
Sources: en.wikipedia.org
Adsorption refrigeration also uses a thermally driven sorption process, but the refrigerant is taken up by a solid adsorbent rather than dissolved in a liquid absorbent. Common adsorption working pairs include water with silica gel or zeolite, and methanol with activated carbon. In a basic adsorption cycle, heating the adsorbent releases refrigerant vapour, which is condensed. When the adsorbent is subsequently cooled, it adsorbs refrigerant vapour again; evaporation of the refrigerant during this part of the cycle produces the cooling effect. Adsorption systems can be driven by low-grade heat sources, including solar or waste heat. Adsorption refrigeration has been extensively studied as an alternative to conventional vapor-compression cooling. Reviews have noted advantages such as the potential use of low-grade thermal energy and relatively simple solid-sorbent systems, while also identifying limitations including comparatively low performance and continuing technical and economic challenges. The main difference from absorption cycle is that in adsorption cycle, the refrigerant (adsorbate) can be ammonia, water, methanol, etc., while the adsorbent is a solid, such as silica gel, activated carbon, or zeolite, while in the absorption cycle the absorbent is liquid. The reason adsorption refrigeration technology has been extensively researched in recent 30 years lies in that the operation of an adsorption refrigeration system is often noiseless, non-corrosive and environmentally friendly.
==== M ==== Dried mangoes – the fruit of the mango tree can be dried. The Philippines produces and exports dried mangoes. India popularly produces 'amchur' or dry mango as whole or powder, popularly used in pickles and masala.
The facilities for each country operate from separate counters inside the railway station building at the platform level. Passengers entering Thailand clear Malaysian and Thai border formalities here in Malaysian territory before boarding their State Railway of Thailand trains which then cross the actual borderline several minutes after departing the station. Passengers from Thailand entering Malaysia are also processed here using the same counters, as there are no separate counters for entry and exit in either country. United Kingdom and the Schengen Area: Border control for travel between the United Kingdom and the Schengen Area features significant prescreening under the juxtaposed controls programme for travel both by ferry and rail. This includes customs and immigration prescreening on both sides of the Channel Tunnel, and immigration-only prescreening for ferry passengers and on the Eurostar between the United Kingdom and stations located in Belgium, France, and the Netherlands. Eurostar and Eurotunnel passengers departing from the Schengen area go through both French, Dutch, or Belgian exit border control and British entry border controls before departures, while passengers departing from the United Kingdom, including those departing for Belgium or the Netherlands, undergo French border controls on British soil. For travel by ferry, French entry border control for ferries between Dover and Calais or Dunkerque takes place at the Port of Dover, whilst French exit and British entry border control take place at Calais and Dunkerque.
polymerase chain reaction (PCR) Any of a wide variety of molecular biology methods involving the rapid production of millions or billions of copies of a specific DNA sequence, allowing scientists to selectively amplify fragments of a very small sample to a quantity large enough to study in detail. In its simplest form, PCR generally involves the incubation of a target DNA sample of known or unknown sequence with a reaction mixture consisting of oligonucleotide primers, a heat-stable DNA polymerase, and free deoxyribonucleotide triphosphates (dNTPs), all of which are supplied in excess. This mixture is then alternately heated and cooled to pre-determined temperatures for pre-determined lengths of time according to a specified pattern which is repeated for many cycles, typically in a thermal cycler which automatically controls the required temperature variations. In each cycle, the most basic of which includes a denaturation phase, annealing phase, and elongation phase, the copies synthesized in the previous cycle are used as templates for synthesis in the next cycle, causing a chain reaction that results in the exponential growth of the total number of copies in the reaction mixture. Amplification by PCR has become a standard technique in virtually all molecular biology laboratories.
== Further reading == Peters, U H (1992), "[Introduction of shock therapy and psychiatric emigration]", Fortschritte der Neurologie-Psychiatrie, vol. 60, no. 9 (published Sep 1992), pp. 356–365, doi:10.1055/s-2007-999155, PMID 1398417, S2CID 71208271 "Manfred J. Sakel", Journal of Clinical and Experimental Psychopathology, vol. 15, no. 3, p. 319, 1954, PMID 13221647 Fink, M (1984), "Meduna and the Origins of Convulsive Therapy", American Journal of Psychiatry, 141(9): 1034-1041 (This historical and biographical paper discusses the introduction of the shock treatment in psychiatry, the role of a theory of the biological antagonism between epilepsy and schizophrenia, and the contributions of Ladislas J. Meduna, Sakel, Ugo Cerletti, and Lucio Bini.) Doroshow, DB: Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards. Journal of the History of Medicine and Allied Sciences, Advance Access published online on November 14, 2006 Jones, K. Insulin coma therapy in schizophrenia. J. Royal Soc. Med, 93: 147-149, 2000.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。